Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
Lists
Only you see this
Abstract
The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population.
BibTeX
@article{li2024efficacy,
author = {Ning Li and Zhi Li and Qiang Fu and Bin Zhang and Jian Zhang and Xiangbin Wan and Chao-min Lu and Jin-Bang Wang and Wenying Deng and Yi-Jie Ma and Liangyu Bie and Mengyu Wang and Jing Li and Qingxin Xia and Wei Chen and Suxia Luo},
title = {{Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study}},
journal = {International Journal of Surgery},
year = {2024},
doi = {10.1097/js9.0000000000001119},
}Loading related content...